Clinomic secures €23M to scale Mona, its AI-based ICU solution

Germany-based Clinomic is expanding its AI-powered assistant Mona to international markets, following a €23 million Series B funding round.

Amid growing challenges in intensive care units such as staff shortages, fragmented data, and administrative overload, Clinomic is pursuing a broader rollout of Mona, its AI-enabled bedside assistant designed to support ICU teams. The company recently raised €23 million in a Series B round co-led by the DeepTech & Climate Fund (DTCF) and a private family office. The funding will go toward product development, global expansion, and further integration of AI-driven tools into critical care workflows.

ICU complexities meet real-time AI integration

Mona addresses long-standing inefficiencies in ICU operations by collecting real-time data from hospital systems and medical devices. The assistant automates documentation, processes lab results, integrates radiology reports, and supports clinical decisions based on live data streams. Designed for direct use at the patient's bedside, Mona functions through voice commands, reducing reliance on physical interfaces and minimizing contamination risks. Using natural language processing, the tool transforms spoken notes into structured medical documentation, significantly cutting time spent on manual entry.

In addition to in-hospital features, Mona enables remote consultations via its secure telemedicine platform, allowing ICU staff to connect with specialists worldwide. The device also includes predictive analytics to anticipate changes in patient condition, flagging anomalies in lab values before they escalate. Its physical setup includes a 24” 4K touchscreen, a wide-angle camera, eight AI-supported microphones, and 5G/WiFi connectivity for seamless integration into hospital systems.

A post-COVID push and FDA ambitions

The COVID-19 pandemic accelerated the adoption of Mona, with healthcare teams using it to manage increased workloads while maintaining care standards. Since then, the system has been implemented in more than 40 hospitals across eight European Union countries. Now, Clinomic is pursuing FDA clearance to introduce Mona to the U.S. market, a move considered key to the company's global strategy.

From clinical insight to startup innovation

Founded in 2019 by Arne Peine, Gernot Marx, and Lukas Martin—intensive care physicians at RWTH Aachen University Hospital—Clinomic grew out of direct experience with the challenges of ICU care. The founders saw clinicians overwhelmed by data, sometimes monitoring up to 1,000 parameters per patient per hour. Faced with limited digital integration and heavy administrative demands, they envisioned a system that could bring clarity and efficiency to ICU operations.

Initial development began in a small room in Aachen, backed by public grants and European Union funding. Over time, the company attracted private capital and scaled its product offerings. Today, Clinomic employs a multidisciplinary team of over 70 experts, including engineers, data scientists, and medical professionals, working to improve critical care delivery through data-driven technologies.